- Home
- CPIX vs AIM Comparison
CPIX vs AIM Comparison
Compare CPIX & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPIX
- AIM
- Stock Information
- Founded
- CPIX 1999
- AIM 1966
- Country
- CPIX United States
- AIM United States
- Employees
- CPIX N/A
- AIM N/A
- Industry
- CPIX Biotechnology: Pharmaceutical Preparations
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPIX Health Care
- AIM Health Care
- Exchange
- CPIX Nasdaq
- AIM Nasdaq
- Market Cap
- CPIX 17.2M
- AIM 15.9M
- IPO Year
- CPIX 2009
- AIM N/A
- Fundamental
- Price
- CPIX $1.17
- AIM $0.24
- Analyst Decision
- CPIX
- AIM Strong Buy
- Analyst Count
- CPIX 0
- AIM 2
- Target Price
- CPIX N/A
- AIM $3.00
- AVG Volume (30 Days)
- CPIX 80.9K
- AIM 220.7K
- Earning Date
- CPIX 11-07-2024
- AIM 11-15-2024
- Dividend Yield
- CPIX N/A
- AIM N/A
- EPS Growth
- CPIX N/A
- AIM N/A
- EPS
- CPIX N/A
- AIM N/A
- Revenue
- CPIX $36,785,442.00
- AIM $201,000.00
- Revenue This Year
- CPIX N/A
- AIM N/A
- Revenue Next Year
- CPIX N/A
- AIM $1,086.80
- P/E Ratio
- CPIX N/A
- AIM N/A
- Revenue Growth
- CPIX N/A
- AIM 19.64
- 52 Week Low
- CPIX $1.07
- AIM $0.21
- 52 Week High
- CPIX $2.36
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- CPIX 43.86
- AIM 41.61
- Support Level
- CPIX $1.15
- AIM $0.24
- Resistance Level
- CPIX $1.21
- AIM $0.27
- Average True Range (ATR)
- CPIX 0.08
- AIM 0.02
- MACD
- CPIX 0.00
- AIM -0.00
- Stochastic Oscillator
- CPIX 42.31
- AIM 24.25
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.